Astellas Pharma Inc.

Astellas Pharma Inc. To Acquire OSI Pharmaceuticals, Inc . Astellas Pharma Inc. , a global pharmaceutical organization, and OSI Pharmaceuticals, Inc. , a biotechnology company centered on the discovery, commercialization and advancement of molecular targeted therapies addressing medical requirements in oncology, diabetes and obesity, have entered right into a definitive merger agreement under which Astellas will acquire OSI. Under the conditions of the merger contract, Astellas increase its offer cost to $57.50 per share, which represents a premium of 55 percent to the closing cost for OSI’s shares of $37.02 on February 26, 2010, the last trading day before the announcement by Astellas of its tender present.

The FDA provides previously granted orphan drug designation for isavuconazole for the treating invasive aspergillosis and invasive mucormycosis. Related StoriesChildren's Memorial Hermann Hospital offers Halloween security tipsBoston Children's and Rock Health synergy to accelerate development of pediatric health technologiesStudy: Post hospital syndrome is significant risk factor for sufferers undergoing elective surgery Invasive candidiasis is a serious hospital-acquired fungal infection that is associated with increased morbidity and mortality using immunocompromised patients. Increasing reviews of Candida resistance to available therapies necessitates the development of fresh antifungals to treat these serious infections, stated Bernie Zeiher, M.D., executive vice president, Global Development and therapeutic area mind of Infectious Disease at Astellas.